Rabies is an acute fatal encephalomyelitis and remains one of the most feared and dreadful zoonotic diseases in the world. According to WHO estimate, Rabies occurs in more than 150 countries and territories. More than 55000 people die off Rabies every year. 40% of people who are beaten by suspected rabid animals are children under 15 years of age. More than 3 billions live in areas in which the disease is an enzootic. Once the clinical signs and symptoms develop, Rabies is almost invariably fatal.The anti-rabies monoclonal antibody cocktail drug being developed at Zydus Research Center, Cadila Healthcare Ltd. is a unique combination of two murine anti-G monoclonal antibodies (MAbs) selected from a panel of five MAbs shortlisted by WHO from collaborating research centres around the world, that bind to two different epitopes on the G protein expressed on the surface of Rabies virus. From panels of anti-rabies Mabs available through its collaborating centers, WHO had initially selected a smaller panel of five murine anti-G MAbs on the basis of their ability to neutralise a broad range of rabies viruses and their heavy chain isotype, selected to be either IgG1 or IgG2a. From this shortlisted panel of WHO, Zydus selected two monoclonals primarily on the basis of their ability to bind two different epitopes on the G protein, and secondarily on the basis of the phenotypic stability of the clone, ability to grow in bioreactors, ability for scalability of the clone, expression levels of the clone etc.